Company Overview and News

to your dashboard

Headline News

Lackluster Industry Group Rank Restricts Amgen (AMGN) Rating

12h investorplace
Portfolio Grader currently ranks Amgen Inc (NASDAQ:AMGN) a Hold. The methodology for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. This represents no change from the previous week and is the same ranking AMGN has had from Portfolio Grader for the last month. (67-0)

Biotech Forum Daily Digest: Behind UniQure's Massive Rally

13h seekingalpha
Sentiment on the biotech sector continues to be somewhat negative especially in the small cap part of this high beta part of the market. (210-0)

Big Biotech In The CRISPR Game: Novartis And Vertex Lead The Pack

15h seekingalpha
CRISPR Therapeutics and Intellia Therapeutics are partnered with the strongest large biotech plays in the space in Vertex and Novartis respectively. (310-0)

Stocks of Drug Upstarts Churn Amid Wider Market’s Steady Climb - Bloomberg

18h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (439-0)

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

2017-10-22 247wallst
Third-quarter earnings reporting season is now well under way. So far, things are looking good. The health care sector has yet to see any significant earnings representation, but that will change during the week of October 23 to October 27. At least eight large biopharma outfits are scheduled to report their latest earnings and revenues. (362-1)

10 More Retirement Stocks to Buy and Hold for the Rest of Your Life

2017-10-20 investorplace
Long-term investing isn’t as easy as it sounds. “Find good stocks to buy them and hold them forever” sounds like solid investing advice. That general principle has led to the success of Warren Buffett, likely the world’s most successful investor, and shareholders in his Berkshire Hathaway Inc. (NYSE:BRK.A,NYSE:BRK.B). (1241-6)

What's in the Cards for Amgen (AMGN) this Earnings Season?

2017-10-20 zacks
Biotech major Amgen Inc. (AMGN - Free Report) will report third-quarter 2017 results on Oct 25 after the market closes. Amgen delivered a positive earnings surprise of 5.83% in the last quarter. (221-0)

Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update

2017-10-20 seekingalpha
Alibaba Group Holdings,, Visa Inc., Apple Inc., and Johnson & Johnson are the largest five individual stock positions. (1097-1)

Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?

2017-10-19 zacks
On Oct 18, 2017, we issued an updated report on ImmunoGen, Inc. (IMGN - Free Report) . (107-0)

Teva Submits BLA to FDA for Migraine Candidate Fremanezumab

2017-10-19 zacks
Teva Pharmaceutical Industries Ltd (TEVA - Free Report) announced the submission of a biologics license application (“BLA”) to the FDA seeking approval for its monoclonal antibody candidate, fremanezumab, as a preventive treatment for migraine. (202-1)

What's in the Cards for Novartis (NVS) This Earnings Season?

2017-10-18 zacks
Swiss pharmaceutical company Novartis AG (NVS - Free Report) is scheduled to report third-quarter 2017 results on Oct 24. (156-0)

Value System: Amgen Looks Undervalued

2017-10-18 seekingalpha
Introducing a new value-oriented quantitative screen for subscribers in my research service: The Data Driven Investor. (171-0)

ImmunoGen to Push Leukemia Candidate into Phase I Trial

2017-10-18 zacks
ImmunoGen, Inc. (IMGN - Free Report) announced that it is planning to move its leukemia candidate, IMGN632, into phase I study before the year-end. The company said that the FDA has completed the safety review of its investigational new drug (IND) application for IMGN632, filed in mid-September for treating patients with CD123-positive hematological malignancies, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). (115-0)

Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen

2017-10-17 zacks
Chicago, IL – October 17, 2017 – Today, Zacks Equity Research discusses the Industry: Pharmaceuticals, Part 1, including Gilead (Nasdaq:(GILD - Free Report)  – Free Report), Teva (NYSE:(TEVA - Free Report)  – Free Report), Pfizer (NYSE:(PFE - Free Report)  – Free Report) and Amgen (Nasdaq:(AMGN - Free Report)  – Free Report). (131-0)

Pharma Industry Outlook - October 2017

2017-10-16 zacks
As we head toward the end of 2017, the pharma and biotech sectors have bounced back nicely with the NYSE ARCA Pharmaceutical Index gaining 14.8%, while the Nasdaq Biotechnology Index is up 26.9%. This is in sharp contrast to 2016, which was a tough year for pharma and biotech stocks with the sector facing a lot of criticism for rising drug prices. (118-0)

Industry Group Rank Metrics Keep Amgen (AMGN) Ratings Upgrade to Hold

2017-10-16 investorplace
Currently, Amgen Inc (NASDAQ:AMGN) has a Hold using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical. (67-0)

Sorrento Therapeutics: Buy, Sell Or Hold After Its Big Rally?

2017-10-13 seekingalpha
After consistently disappointing shareholders since going public in early 2014, the shares of Sorrento Therapeutics have staged a huge rally recently. (85-3)

The Lower Volatility Stock Portfolio For Retirees And Others

2017-10-12 seekingalpha
I recently had a look at SPDR sectors through the last two major market corrections in search of lower volatility or drawdown. (333-1)

NIH partners 11 drugmakers to accelerate cancer therapy research

2017-10-12 reuters
(Reuters) - The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body’s immune system to fight cancer. (251-0)

Your Daily Pharma Scoop: Alexion's Catalysts, Amgen's Prolia, Ultragenyx Borosumab

2017-10-11 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (288-3)

Short Sellers Grow More Selective on Major Biotechs

2017-10-11 247wallst
The short interest data are out for the most recent settlement date, September 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that his repeal of the ACA looking uncertain, the health care rally is called into question. (287-0)

Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

2017-10-11 zacks
Companies like Amgen (AMGN - Free Report) and Regeneron (REGN - Free Report) were in the news with Amgen providing pipeline and regulatory updates while Regeneron and partner Sanofi got some good news with an appeals court ruling in their favor in the PCSK9 inhibitor lawsuit against Amgen. Recap of the Week’s Most Important Stories Phase II Combination Data on Amgen’s Imlygic Published: Positive data on Amgen’s oncolytic viral therapy, Imlygic, when used in combination with Bristol-Myers Squibb’s Yervoy were published in the Journal of Clinical Oncology. (383-0)

An In-Depth Look At Alexion's Competition And Upcoming Catalysts

2017-10-10 seekingalpha
Alexion Pharmaceuticals, Inc. (ALXN) is a biopharmaceutical company with three marketed drugs, a promising pipeline member in ALXN1210, and a market cap of over $31 billion. ALXN’s major source of revenue, however, a drug called eculizumab (marketed as Soliris), may face competition in the future. Evaluating the viability of the threat posed by ALXN’s competitors is a key step before opening or closing a position and the focus of this article. (168-0)

Amgen Label Expansion Application for Prolia Accepted by FDA

2017-10-10 zacks
Amgen, Inc. (AMGN - Free Report) announced that the FDA has accepted its regulatory application in the United States seeking label expansion for Prolia for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The FDA is expected to give its decision on May 28 next year. (133-0)

Your Daily Pharma Scoop: Synergy's Cash Position, Flexion's Zilretta Approval, Keryx Major Catalyst

2017-10-10 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (963-5)

CUSIP: 031162900